AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$52.03 USD
+0.17 (0.33%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $52.04 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$52.03 USD
+0.17 (0.33%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $52.04 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
McKesson (MCK) Announces Availability of FDA-Cleared Drug for MCL
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MCL.
Thermo Fisher (TMO) Rides on Strong End Markets, New Launches
by Zacks Equity Research
Thermo Fisher's (TMO) newly-launched Gibco CTS DynaCellect Magnetic Separation System is helping customers advance their cell and gene therapy programs.
Charles River (CRL) Introduces Novel IgY-Based ELISA Kit
by Zacks Equity Research
Charles River's (CRL) HCP-ELISA is built on its HCP-GAPex service, enhancing the efficiency and efficacy of HCP assay development.
ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers
by Zacks Equity Research
ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) on continued partnership growth and a strong focus on strategic execution.
Abbott (ABT) to Expand Vascular Device Line With New Buyout
by Zacks Equity Research
Abbott's (ABT) latest deal will help gain access to Cardiovascular System's leading atherectomy device to treat vascular disease.
AMN Healthcare (AMN) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect soft demand across the majority of its segments.
Abbott (ABT) EPD Growth Continues Amid Macroeconomic Challenges
by Zacks Equity Research
At Abbott (ABT), Medical Device sales growth is led by strong performance in Electrophysiology, Structural Heart and Diabetes Care.
BD's (BDX) Latest Combination Test Receives the FDA's EUA
by Zacks Equity Research
BD's (BDX) new combination test is likely to significantly aid clinicians in treating patients in the current and future respiratory virus seasons.
AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $93.60, moving -1.84% from the previous trading session.
3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLY
LabCorp's (LH) New Launches, Planned Spinoff to Aid Growth
by Zacks Equity Research
In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.
AMN or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AMN Healthcare Services (AMN) and Sorrento Therapeutics (SRNE) have performed compared to their sector so far this year.
Hologic (HOLX) Q1 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
Lower COVID-19 assays sales and supply chain challenges related to semiconductor chips dent Hologic's (HOLX) top line in Q1.
Thermo Fisher (TMO) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Robust year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments boost Thermo Fisher's (TMO) Q4 revenues.
Edwards Lifesciences (EW) Q4 Earnings Top, Margins Increase
by Zacks Equity Research
Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL platform in Europe.
Integer Holdings (ITGR) Announces Solid Preliminary Q4 Revenues
by Zacks Equity Research
Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.
AMN Healthcare Services (AMN) Stock Moves -0.88%: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $95.47, moving -0.88% from the previous trading session.
AMN Healthcare Services (AMN) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $96.75, making no change from the previous trading session.
Here's Why You Should Retain DaVita (DVA) Stock for Now
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.
Intuitive Surgical (ISRG) Falls Following Q4 Earnings Miss
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results reflect healthy demand for procedures, partially offset by lower system sales and unfavorable currency. Procedure volume in China suffers.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.